Danielle Styvie KOUMBA MAVOUNGOU

Ms. Danielle Styvie KOUMBA MAVOUNGOU

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 June 2024 in Viruses
Verified
Journal Article
Open access
PDF file
DMDanielle Styvie KOUMBA MAVOUNGOU
Danielle Styvie KOUMBA MAVOUNGOU
LKLinda Bohou Kombila
Linda Bohou Kombila
LMLONGO PENDY Michel
LONGO PENDY Michel
SMSchedy E. Koumba Moukouama
Schedy E. Koumba Moukouama
SLSonia Etenna Lekana-Douki
Sonia Etenna Lekana-Douki
NNN'DILIMABAKA Nadine
N'DILIMABAKA Nadine
Hepatitis B virus (HBV) infection leads to around 800,000 deaths yearly and is considered to be a major public health problem worldwide. However, HBV origins remain poorly understood. Here, we looked for bat HBV (BtHBV) in different bat species in Gabon to investigate the role of these animals as carriers of ancestral hepadnaviruses because these viruses are much more diverse in bats than in other host species. DNA was extracted from 859 bat livers belonging to 11 species collected in caves and villages in the southeast of Gabon and analyzed using PCRs targeting the surface gene. Positive samples were sequenced using the Sanger method. BtHBV DNA was detected in 64 (7.4%) individuals belonging to eight species mainly collected in caves. Thirty-six (36) sequences among the 37 obtained after sequencing were phylogenetically close to the RBHBV strain recently isolated in Gabonese bats, while the remaining sequence was close to a rodent HBV strain isolated in America. The generalized linear mixed model showed that the variable species best explained the occurrence of BtHBV infection in bats. The discovery of a BtHBV strain homologous to a rodent strain in bats raises the possibility that these animals may be carriers of ancestral hepadnaviruses.

12 September 2023 in IJID Regions
Verified
Journal Article
Open access
DMDanielle Styvie KOUMBA MAVOUNGOU
Danielle Styvie KOUMBA MAVOUNGOU
NNNadine N'DIlimabaka
Nadine N'DIlimabaka
EEeric elguero
eric elguero
LKLinda Bohou Kombila
Linda Bohou Kombila
ADAbdoulaye Diane
Abdoulaye Diane
Avelin F. AghokengAvelin F. Aghokeng
Avelin F. Aghokeng
Hepatitis B virus (HBV) infection remains a public health threat in middle- and low-income countries, where mother-to-child transmission plays an important role. The aim of this study was to assess the burden of this infection among pregnant women in southern Gabon and the risk of vertical transmission. The study was a prospective investigation conducted from April 2021 to January 2022. Study participants were pregnant women aged 18 and over attending antenatal clinics in Franceville. Blood samples were collected to test for HBV surface antigen, anti-hepatitis B core, hepatitis B e antigen, and anti-hepatitis B e markers and to assess HBV infection. We recruited 901 women with a median age of 26 years (interquartile range: 21-32). Overall prevalence of infection was 3.9% (confidence interval: 2.7-5.4%). 418/901 or 46.4% were anti-hepatitis B core positive. Among HBV surface antigen-positive women, 1/35 were hepatitis B e antigen-positive with a viral load >200,000 IU/ml. Over 64% of participants had no information about HBV infection, and none knew that the virus could be transmitted from mother to child. This study reveals a low HBV prevalence in pregnant women in Gabon and a low risk of vertical transmission of the virus. However, the rate of exposure of the population to the virus remains high and calls for improving actions and interventions for potential elimination goals.

23 July 2024 in The American Journal of Tropical Medicine and Hygiene
Verified
Journal Article
Open access
PDF file
LKLinda Bohou Kombila
Linda Bohou Kombila
SLSolène Lerolle
Solène Lerolle
IMIllich Manfred Mombo
Illich Manfred Mombo
LMLONGO PENDY Michel
LONGO PENDY Michel
DMDanielle Styvie KOUMBA MAVOUNGOU
Danielle Styvie KOUMBA MAVOUNGOU
PBPierre Becquart
Pierre Becquart
Crimean-Congo hemorrhagic fever (CCHF) is a tick-borne viral disease with a mortality rate reaching up to 40% in humans. Currently, CCHF affects three continents: Asia, Europe, and Africa. An increase in confirmed cases in Africa has been observed since 2000. In Central Africa, several countries have reported the circulation of CCHV virus (CCHFV). However, in Gabon, there is a lack of recent data on the circulation of the virus in the Gabonese population. To provide an overview of the epidemiological situation in Gabon, we tested 3,081 human serum samples collected between 2005 and 2008 in villages throughout the country for anti-CCHFV antibodies. Using a double-antigen ELISA kit, our study found 15/3,081 samples positive for CCHFV. These positive samples were also tested using the Blackbox CCHFV IgG kit and the Luminex technique. These analyses confirmed seven and four positives for the Blackbox CCHFV IgG kit and the Luminex technique, respectively. This study suggests low circulation of CCHFV in the rural human population of Gabon. Competent authorities must survey CCHFV to identify and prevent clinical cases in the human population.

13 January 2022 in IJID Regions
Verified
Journal Article
Open access
NNN'DILIMABAKA Nadine
N'DILIMABAKA Nadine
DMDanielle Styvie KOUMBA MAVOUNGOU
Danielle Styvie KOUMBA MAVOUNGOU
VSVladimir Soami
Vladimir Soami
LKLinda Bohou Kombila
Linda Bohou Kombila
RMRose Marlène Mouguiama
Rose Marlène Mouguiama
GMGael Darren MAGANGA
Gael Darren MAGANGA
Rabies is a zoonotic neurological life-threatening neglected tropical disease present worldwide and Gabon is listed as an endemic country. However, despite strong clinical suspicion in humans and molecular confirmation of infections with the rabies virus (RABV) in dogs for several decades, no human molecularly confirmed case in Gabon has ever been reported. In this study we describe two cases of human rabies and provide the first molecular diagnostic report on suspected human rabies cases in Gabon. Our results showed that the RABVs isolated from the victims are closely related to other RABV strains, previously isolated more than 20 years ago from the brains of Gabonese dogs, belonging to African 1A subclade in the Cosmopolitan lineage, suggesting that only this species circulates in the country. Because both patients had a history of dog bites a few weeks before the symptom's onset and the main causative agent of human rabies worldwide is dog-associated rabies virus, we deduce that dogs are likely to be the source of human infection in this study.

14 May 2026 in Pathogens
Verified
Journal Article
Open access
PDF file
DMDanielle Styvie KOUMBA MAVOUNGOU
Danielle Styvie KOUMBA MAVOUNGOU
Larson BoundengaLarson Boundenga
Larson Boundenga
SLSonia Etenna Lekana-Douki
Sonia Etenna Lekana-Douki
LMLONGO PENDY Michel
LONGO PENDY Michel
SMSchedy E. Koumba Moukouama
Schedy E. Koumba Moukouama
NNN'DILIMABAKA Nadine
N'DILIMABAKA Nadine
Orthohepanaviruses are viruses that infect a number of mammals, including humans and non-human primates. However, previous studies in great apes in Gabon in 2001 found one strain of hepadnavirus (HBV ChBassi strain) displaying genetic recombination between human, gorilla and chimpanzee strains, suggesting cross-species transmissions among primates. The aim of this study was to evaluate the presence of HBV DNA in non-human primates (NHPs) and to compare it with human HBV strains in order to assess the zoonotic potential. We analyzed feces from 1891 NHPs, collected in forests in Gabon, to find human HBV-related hepadnaviruses by amplifying a portion of the S gene using hemi-nested techniques, followed by sequencing. A total of 51 samples were PCR-positive. Thirteen of the fourteen sequences obtained after sequencing were phylogenetically more closely related to chimpanzee HBV strains, while the fourteenth sequence was associated with the ChBassi HBV strain. This study shows that HBV infection is endemic in wild-born great apes in Gabon. The detection of a strain genetically close to the Bassi strain (a potential zoonotic strain) highlights the need for more in-depth studies to provide an effective response as part of the ‘One Health’ initiative.